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Abstract. The aim of the study was to assess the immunohistochemical (IHC) profiles of SRC3, Pax2, ER, PgR, 
Her2, EGFR, CK5/6, and Ki67 proteins in breast-cancer brain metastasis. The study utilized tumor samples 
from 30 metastatic patients and calculated correlations between all IHC variables. In fourteen cases, primary 
breast cancers paired with secondary deposits were analyzed. We evaluated the association between IHC status 
in the primary and secondary deposits, grade, and  histotype of the tumors. The examination of the metastatic 
deposits in all 30 patients resulted in positive detection in the following cases: SRC3 in 20 cases (66.6%), Pax2 in 
22 (73.3%), ER in 22 (73.3%), PgR in 25 (83.3%), Her2 in 10 (33.3%), EGFR in 12 (40%), CK5/6 in 7 (23.3%), 
and Ki67 in 23 (76.6%). Grade 2 was found in 13.3% of all patients, and grade 3 in 86.7%. SRC3 and Pax2 were 
positive in both G2 and G3. Invasive lobular carcinoma and invasive ductal carcinoma were diagnosed in 23.3% 
and 76.7% of cases, respectively. There were no differences between the IHC expression of the studied proteins 
in either grading or histotype of the tumors. In the IHC profiles, which included SRC3, Pax2, ER, PgR, Her2, 
CK5/6, Ki67, and EGFR, we found no statistically significant differences between the primary cancer and the 
brain metastasis. In our study of metastatic breast carcinoma deposits, there was no correlation between SRC3, 
Pax2 status and histotype, and tumor grade. The IHC status of the paired primary and metastatic deposits did 
not differ in a statistically significant manner. (Folia Histochemica et Cytobiologica 2013, Vol. 51, No. 3, 213–218)
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Breast cancer is the second most common cause of bra-
in metastasis. Central nervous system (CNS) metastatic 
deposits during the course of breast cancer have un-
favorable prognosis, and are associated with indicators 
such as a young age at diagnosis, a disease-free interval 
of less than one year, estrogen receptor negativity, and 
Her2 receptor positivity. The incidence may be caused 
by the clonal selection of tumor cells induced by new 
treatment modalities such as trastuzumab (Herceptin). 
The development of breast-cancer brain metastasis 
depends on numerous factors, such as invasiveness, 
migration, adhesion, extracellular matrix degradation, 
revascularization, and proliferation. One of the most 
significant characteristics of malignant breast-cancer 
cells is their ability to penetrate the blood-brain barrier 
and subsequently invade the brain tissue.
Estrogens are major factors in the pathogenesis, 
progression, growth, differentiation, and survival of 
breast cancer. The cellular effects of estrogen are 
primarily mediated by estrogen receptor alpha (ERa). 
ERa is expressed in 70% of breast cancers [1], and 
endocrine treatment is a key modality in the treatment 
of the vast majority of breast-cancer patients. 
ERa is a transcription factor that acts by regula-
ting gene expression, either through direct binding 
to estrogen response elements, or by recruitment 
of gene promoters through interactions with other 
transcription factors. The p160 coactivators — steroid 
receptor coactivator-1 (SRC-1), SRC-2, and SRC-3 
— are critical to ERa functioning. SRC-3 is also 
known as AIB1 (Amplified In Breast cancer 1). 
A large proportion of patients who develop resistance 
to endocrine therapies respond to alternative endo-
crine agents, demonstrating that ERa continues to 
play a critical role in breast-cancer cell proliferation 
in breast tumors. Steroid Receptor Coactivator-3 
(SRC-3/AIB1/ACTR/pCIP/RAC3) is a member of the 
p160 coactivator family and plays an important role in 
cell growth, reproduction, metabolism, and cytokine 
signaling [1–3]. There is growing evidence for the im-
portance of SRC-3 in cell growth and the oncogenesis 
of breast cancer [3, 4]. The SRC-3 gene is amplified 
in up to 10% of human breast cancers, and its high 
expression is found in 64% of cases [5, 6]. SRC-3 
amplification is preferentially found in breast tumors 
that are positive for ERa and Progesterone Receptor 
(PgR) [7]. It has been shown that the high levels of 
SRC-3 expression in breast cancer are associated 
with a decreased risk of relapse in untreated patients 
[8]. However, in breast-cancer patients treated with 
tamoxifen, SRC-3 overexpression in tumor tissu e acts 
as a marker of disease relapse. Furthermore, when 
the expression of SRC-3 and epidermal growth factor 
receptor 2 (Her2) were considered together, those 
patients whose tumors expressed high levels of both 
SRC-3 and Her2 experienced worse outcomes with 
tamoxifen therapy than all other patients combined 
[8]. This indicates that tamoxifen antitumor activity 
in breast cancer may be partly determined by SRC-3 
and Her2 tumor levels [8]. The Pair box (Pax) gene 
family consists of nine genes that encode transcription 
factors [9]. The Pax2 protein competes with SRC-3 
for the binding and regulation of Her2 transcription, 
which determines tamoxifen response in breast-cancer 
cells [10]. Epidermal growth-factor receptor (EGFR) 
activates the tumor cells through its specific surface 
receptor, and a higher expression of EGFR has been 
found in metastatic brain disease [11]. 
Material and methods
Patients. We studied 30 brain metastatic breast-cancer 
deposits in cooperation with Imperial College London in 
the UK and the Charles University Teaching Hospital in 
Prague, Czech Republic. The project was approved by the 
local ethics committees. All of the patients had been previo-
usly treated for brain metastasis, and all of the brain tissue 
samples were obtained during neurosurgical procedures. 
23 patients were treated for primary breast-cancer tumors 
with standard anticancer drugs, such as docetaxel, cisplatin, 
and etoposide, in the course of standard oncological regi-
mes. None of these anticancer medications are capable of 
penetrating the blood-brain barrier. 
Sections of paraffin-embedded tissues were studied 
through immunohistochemistry (IHC), using monoclonal 
antibodies against ER, PgR, Her2, SRC3, Pax2, CK5/6, Ki67, 
and EGFR proteins. All the primary and secondary breast-
cancer deposits underwent IHC staining processes at one 
time. Five-micrometer sections of each paraffin-embedded 
specimen were stained with hematoxylin and eosin, in order 
to verify the presence of adequate numbers of invasive tumor 
cells and the tumor grade. Cases were considered positive 
for ER, PgR, Her2, SRC3, Pax2, CK5/6, Ki67, and EGFR 
when at least 10% of the tumor cells showed distinct positive 
staining. Immunohistochemistry for ER (clone SP1, Venta-
na, Tucson, AZ, USA), PgR (clone IE2, Ventana, Tucson, 
AZ, USA), and Her2 (clone 4B5, Ventana, Tucson, AZ, 
USA) was used to semiquantitatively measure ER, PgR, 
and Her2 protein expression (Ventana Benchmark XT, 
Ultraview detection kit, Tucson, AZ, USA). 
Antigen retrieval was performed by heating the slides for 
30 minutes in HCl. Antibodies were applied at room temperature: 
ER for 28 minutes, PgR for 24 minutes, and Her2 for 16 minu-
tes. Immunohistochemistry for EGFR (Bondmax, Bucks, Uni-
ted Kingdom) was used to semiquantitatively measure EGFR 
protein expression (Bondmax, Leica, Bucks, United Kingdom), 
and a Bond Polymer Detection Kit DS9800 was employed 
(Leica, Bucks, United Kingdom). Antigen retrieval was perfor-
med by heating the slides in protease digestive enzyme (Leica, 
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Bucks, United Kingdom) for 10 minutes. EGFR antibody 
was applied for 30 minutes in a 1:50 concentration. Immu-
nohistochemical staining for Ki67 (Bondmax) and CK5/6 was 
used to semiquantitatively measure Ki67 and CK5/6 protein 
expression (Bondmax, Leica, and Bond Polymer Detection 
Kit DS9800). Antigen retrieval was performed by heating the 
slides for 30 minutes (Ki67) and 20 minutes (CK5/6) in ER1 
(Bond Epitope Retrieval Solution 1, Leica, Bucks, United 
Kingdom). The antibodies were applied for 30 minutes at 
concentrations of 1:100 (Ki67) and 1:200 (CK5/6) [12].
Immunohistochemistry for AIB1 (BD Transduction 
Laboratories, San Diego, CA, USA) was used to semiquan-
titatively measure AIB1 protein expression (Bond Polymer 
Detection Kit DS9800, Leica, Bucks, United Kingdom). In 
summary, antigen retrieval was performed by heating the sli-
des for 30 minutes in ER2 (Bond Epitope Retrieval Solution 
2, Leica, Bucks, United Kingdom). AIB1 antibody was ap-
plied for 30 minutes at a concentration of 1:500 [13]. PAX2 
immunohistochemistry was performed on an automated 
BondMax Immunostainer (Leica, Bucks, United Kingdom) 
using anti-PAX2 antibody (ab38738; Abcam, Cambridge, 
United Kingdom) at a dilution of 1:100 (Table 1). 
Statistical analysis. Histological data and patients’ ages were 
used for the statistical analysis. All histological slides were 
independently checked by two pathologists. To evaluate the 
association between all the immunohistochemical variables, 
Spearman’s and Kendall’s correlation coefficients were 
calculated. To compare the immunohistochemical profiles 
of SRC3, Pax2, ER, PgR, Her2, CK5/6, Ki67, and EGFR 
among primary and brain metastasis, both the Wilcoxon 
paired signed-rank test and McNemar’s chi-square test were 
utilized (STATISTICA v. 9, StatSoft Inc., Tulsa, OK, USA). 
Results
Thirty breast-cancer patients with brain metastasis 
were included in the present study. The median age 
at the time of primary tumor diagnosis was 54 years 
of age (range 42–83) and the average age was 57. 
Grade 2  was diagnosed in 4 out of 30 cases (13.3%) 
and grade 3 in 26 out of 30 cases (86.7%). Invasive 
lobular carcinoma was diagnosed in 7 out of 30 cases 
(23.3%), and invasive ductal carcinoma in 23 out of 
30 cases (76.7%). One case of invasive ductal carcinoma 
was mixed with ductal carcinoma in situ. All patients 
had at least one lymphatic node test positive for me-
tastatic tumor cells.
To assess the association between all immunohi-
stochemically observed variables, both Spearman’s 
and the more suitable Kendall’s correlation coef-
ficients were calculated. Spearman’s correlation 
coefficient only showed one statistically significant 
correlation, between EGFR and CK5/6 (P < 0.004); 
Kendall’s correlation coefficient indicated statistically 
significant associations in the following cases: EGFR 
vs. CK5/6 (P < 0.001), ER vs. PR (P < 0.01), AIB1 
vs. CK5/6, PAX2 vs. Her2, and PAX2 vs. EGFR 
(P < 0.04 in last 3 cases).
Of the metastatic deposits taken from the 30 pa-
tients, SRC3 was positive in 20 cases (66.6%), Pax2 
in 22 (73.3%), ER in 22 (73.3%), PgR in 25 (83.3%), 
Her2 in 10 (33.3%), EGFR in 12 (40%), CK5/6 in 
7 (23.3%), and Ki67 in 23 (76.6%) (Table 2). In fourteen 
cases, primary breast cancers paired with secondary 
deposits were analyzed. In sixteen cases, the primary 
breast-cancer deposits were not available. Out of 
14 cases of primary tumors, SRC3 was positive in 
8 (57.1%), Pax2 in 11 (78.5%), ER in 9 (64.2%), PgR 
in 7 (50%), Her2 in 4 (28.6%), EGFR in 2 (14.3%), 
CK5/6 in 6 (42.9%), and Ki67 in 10 (71.4%). 
Among the metastatic deposits, almost all of the 
samples were positive for Ki67 (92.9%); more than 
one half of the samples were positive for SRC-3, Pax2, 
and EGFR (57.1%); CK5/6 was positive in 42.9%; 
Her2 in 35.7%; ER 21.4%; and PgR 14.3% of cases 
(Table 3). 
The paired deposits (total n = 14) allow a direct 
comparison of the primary tumor and the corre-
sponding metastasis. Surprisingly, the majority of 
cases revealed unstable marker expression (Table 2). 
Constant SRC3 status was observed in 10 out of 
14 cases (71%), while 2 cases converted to SRC3 
negative (14.3%). Newly acquired SRC3 expression 
was detected in 2 cases (14.3%). Constant Pax2 status 
was only observed in 7 of the 14 cases (50%). Five 
cases converted to Pax2 negative (35.7%), and 2 cases 
converted to Pax2 positive (14.3%). The constancy of 
ER was observed in only 4 cases (28.6%), with swit-
ching observed in 10 cases (71.4%). The switching of 
PgR, Her2, EGFR, CK5/6, and Ki67 was observed 
in 50%, 21.4%, 57.1%, 28.6% and 21.4% of cases, 
respectively. Interestingly, the highest constancy was 
observed in Her2 and Ki67 staining. For Her2, a loss 
of expression was found in two cases (14.3%) and 
Table 1. Source of primary antibodies used in the study
Antibody Company
ER (clone SP1) Ventana, Tucson, Arizona, AZ, USA
PgR (clone IE2) Ventana, Tucson, Arizona, AZ, USA
Her2 (clone 4B5) Ventana, Tucson, Arizona, AZ, USA
EGFR Bondmax, Bucks, United Kingdom
Ki67 Bondmax, Bucks, United Kingdom
CK5/6 Bondmax, Bucks, United Kingdom
AIB1 BD Transduction Laboratories, San Diego, 
CA, USA
Pax2 (ab38738) Abcam, Cambridge, United Kingdom
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a gain was encountered in one case (7.1%). For Ki67, 
gains were encountered in all three cases of switching 
(21.4%) (Table 3). To determine whether the changes 
between primary tumors and secondary metastatic 
deposits were statistically significant, the Wilcoxon 
paired signed-rank test and McNemar’s chi-square 
test were used. There were no statistically significant 
differences among the observed variables at a p-value 
of 0.05. Differences at a significance level of a = 10% 
(i.e. P < 0.1) were only found for EGFR (P = 0.059), 
PR (P = 0.091), and ER (P = 0.093) (Table 3).
Discussion
The incidence of brain metastasis in breast cancer 
is increasing. The percentage of breast cancer cases 
involving the CNS is between 10 and 40%, depending 
on the study [14]. Only 5% of patients with ER-po-
sitive primary tumors developed CNS secondary 
deposits, while 9% of ER negative breast-cancer 
patients developed CNS metastasis [15]. The rate of 
discordance between primary tumor and secondary 
deposits has been reported to range from 28% to 42% 
for ER, and was 17% for PgR [14, 15]. Depending on 
the study and the techniques applied, the discordance 
rates of Her2 ranged between 0% and 37% [16–20]. 
Hurtado et al. showed that PAX2 competes with SRC-
3 for binding and regulation of HER-2 transcription. 
Human breast cancers that were PAX2 positive and 
SRC-3 negative had the lowest recurrence rate, and 
the relationship between PAX2 and SRC-3, with re-
gard to levels that determine relapses, were found to 
be inversely dependent (P < 0.03) [10]. This suggests 
a transcriptional link between the two subtypes of 
breast cancer, namely ER-positive and HER2-po-
sitive tumors. This mechanism may also lead to the 
subsequent activation of SRC-3 via phosphorylation.
At present, there is no publication comparing 
SRC3 and Pax2 protein expression in primary and se-
condary deposits of breast cancer. Our study involved 
only a small number of patients, but it is nevertheless 
remarkable that the biological characteristics of the 
CNS deposits were sometimes transformed with re-
spect to that of the primary tumor.
Immunohistochemical profiles were performed 
for 30 metastatic deposits using antigens for SRC3, 
Pax2, ER, PgR, Her2, CK5/6, Ki67, and EGFR. SRC 
was positive in 66.6% of cases and Pax2 in 73.3%. No 
correlation was seen between the patient’s age, cancer 
grade, histotype, lymphatic node status, and protein 
expression (Figures 1–8). 
Using all seven antigens, the primary tumor’s protein 
expression differed from that of the brain deposits in 
13 cases out of 14 (93%). Constant expression of SRC3 
and Pax2 was seen in 71% and 50% of cases, respectively. 
The highest level of protein detection was observed with 
Ki67, in 10 cases out of 14 (71.4%); the greatest gain was 
observed with EGFR in 7 cases; and the biggest loss of 
protein was observed with ER in 8 cases.
In conclusion, our IHC study suggests that not all 
distant metastases have the same protein expression as 
the primary tumor. The reassessment of these protein 
Table 3. Changes in immunohistochemically defined protein expression in paired samples from primary breast cancer and 
secondary CNS deposits (n = 14)
Primary/metastasis Constant expression Pos./pos. N eg./neg. Gain in relation 
to primary tumor 
Loss in relation 
to primary tumor
SRC3 10 (71%) 6 4 2 2
Pax2 7 (50%) 6 1 2 5
ER 4 (28.6%) 1 3 2 8
PgR 7 (50%) 1 6 1 6
Her2 11 (78.6%) 3 8 2 1
EGFR 6 (42.3%) 1 5 7 1
CK5/6 10 (71.4%) 4 6 2 2
Ki67 11 (78.6%) 10 1 3 0
Table 2. Summary of positive primary and metastatic bre-
ast-cancer deposits (n = 30)
Antigen % of positive 
primary deposits
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Figure 1. Expression of estrogen receptors (ER) in brain 
tissue. The sections were stained by IHC as described in 
Methods. Original magnification ×20
Figure 2. Expression of progersterone receptors (PgR) in 
brain tissue. The sections were stained by IHC as described 
in Methods. Original magnification ×20
Figure 3. Expression of human epidermal growth factor 
receptor 2 (Her2) in brain tissue. The sections were stained 
by IHC as described in Methods. Original magnification ×20
Figure 5. Expression of epidermal growth factor receptors 
(EGFR) in brain. The sections were stained by IHC as 
described in Methods. Original magnification ×20
Figure 6. Expression of the presence of cytokeratin 5,6 
(CK5/6) in brain tissue. The sections were stained by IHC 
as described in Methods. Original magnification ×20
Figure 4. Expression of Ki67 receptors (Ki67) in brain 
tissue. The sections were stained by IHC as described in 
Methods. Original magnification ×20
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expressions in metastatic deposits may be useful for 
optimizing oncological treatments.
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Figure 8. Expression of paired box 2 (Pax2) receptors in 
brain tissue. The sections were stained by IHC as described 
in Methods. Original magnification ×20
Figure 7. Expression of AIB1 (Amplified in Breast Cancer 
1) in brain. The sections were stained by IHC as described 
in Methods. Original magnification ×20
